Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Emilie Castermans

Combined Treatment With Octreotide LAR and Pegvisomant in Patients With Gigantism - Acromegaly: Clinical Evaluation and Genetic Screening

Endocrine Abstracts

2016

English

Nonmyeloablative Stem Cell Transplantation With CD8-Depleted or Unmanipulated Peripheral Blood Stem Cells: A Prospective Randomized Trial.

English

Related publications

Long-Term Treatment of Acromegaly and Gigantism With Octreotide (SMS 201-995)

Folia Endocrinologica Japonica

1992

English

Glucose Homeostasis and Safety in Patients With Acromegaly Converted From Long-Acting Octreotide to Pegvisomant

Journal of Clinical Endocrinology and Metabolism

Biochemistry

Endocrinology

Clinical Biochemistry

English

Change in Quality of Life in Patients With Acromegaly After Treatment With Octreotide LAR: First Application of AcroQoL in Korea

BMJ Open

Medicine

2015

English

Long-Term Treatment With Pegvisomant: Observations From 2090 Acromegaly Patients in ACROSTUDY.

European Journal of Endocrinology

English

A Comparison Between Octreotide-Lar and Lanreotide-Sr in the Chronic Treatment of Acromegaly

European Journal of Endocrinology

English

Case Study of a 15-Year-Old Boy With McCune-Albright Syndrome Combined With Pituitary Gigantism: Effect of Octreotide-Long Acting Release (LAR) and Cabergoline Therapy

English

Differing Effects on Gall-Bladder Motility of Lanreotide SR and Octreotide LAR for Treatment of Acromegaly

European Journal of Endocrinology

English

Octreotide LAR Dosage and Survival Among Elderly Patients With Distant-Stage Neuroendocrine Tumors

English

Treatment of Recurrent Gastrointestinal Haemorrhage in a Patient With Von Willebrand's Disease With Octreotide LAR and Propranolol

Gut

Gastroenterology

2005

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Emilie Castermans

Combined Treatment With Octreotide LAR and Pegvisomant in Patients With Gigantism - Acromegaly: Clinical Evaluation and Genetic Screening

Nonmyeloablative Stem Cell Transplantation With CD8-Depleted or Unmanipulated Peripheral Blood Stem Cells: A Prospective Randomized Trial.

Related publications

Long-Term Treatment of Acromegaly and Gigantism With Octreotide (SMS 201-995)

Glucose Homeostasis and Safety in Patients With Acromegaly Converted From Long-Acting Octreotide to Pegvisomant

Change in Quality of Life in Patients With Acromegaly After Treatment With Octreotide LAR: First Application of AcroQoL in Korea

Long-Term Treatment With Pegvisomant: Observations From 2090 Acromegaly Patients in ACROSTUDY.

A Comparison Between Octreotide-Lar and Lanreotide-Sr in the Chronic Treatment of Acromegaly

Case Study of a 15-Year-Old Boy With McCune-Albright Syndrome Combined With Pituitary Gigantism: Effect of Octreotide-Long Acting Release (LAR) and Cabergoline Therapy

Differing Effects on Gall-Bladder Motility of Lanreotide SR and Octreotide LAR for Treatment of Acromegaly

Octreotide LAR Dosage and Survival Among Elderly Patients With Distant-Stage Neuroendocrine Tumors

Treatment of Recurrent Gastrointestinal Haemorrhage in a Patient With Von Willebrand's Disease With Octreotide LAR and Propranolol